This year, money has been funneling into companies that apply artificial intelligence to healthcare, from diagnostics to speech recognition software. The latest recipient is New York-based Prognos, which says it just closed a $20.5 million Series C round from a group of prominent insurers, drug makers, and venture capital investors.
Prognos’s A.I.-related software aims to identify patients who suffer from conditions such as diabetes, asthma, and non-small cell lung cancer by analyzing laboratory and diagnostics records. Prognos says it can help life science companies find patients who might benefit from the companies’ treatments, and at an earlier stage of their conditions. It currently works with 25 life science brands, Prognos says.
Read Complete Article